Monthly Archives: May 2023

Health

The Halpern Law Firm Continues to Grow, Welcoming Five New Team Members

Leave a comment


Pennsylvania mesothelioma lawyer

For over 30 years, The Halpern Law Firm has relentlessly pursued justice for asbestos and mesothelioma victims in Pennsylvania.

“The diverse skills and experiences of our new team members will undoubtedly contribute to our ongoing mission of representing and fighting for the rights of asbestos victims” – Dave Halpern, Founding Attorney of The Halpern Law Firm.


PHILADELPHIA (PRWEB)

The Halpern Law Firm, a preeminent Pennsylvania-based law firm specializing in asbestos and mesothelioma cases, continues to thrive and is delighted to announce the addition of five new members to their dynamic team: Chelsea Williams, Mark Watkins, Daniel Liberio, Thaddeus Kotarski, and Jeff Nelson. This expansion further reinforces the firm’s unwavering commitment to providing exceptional legal services to victims of mesothelioma and other asbestos related diseases.

Daniel Liberio is a 2023 graduate of Temple University Beasley School of Law and has joined our firm as a Law Clerk. With previous legal experience in the public interest arena, within government through the Bucks County District Attorney’s Office, and in private civil practice, Daniel’s experience will bring a fresh perspective to our legal team. Upon completion of the Pennsylvania Bar Examination, he will transition to the role of Associate Attorney.

Thaddeus Kotarski, a recent graduate of the University of Pittsburgh School of Law, brings a diverse and impressive legal background to the team. Thaddeus has worked on a variety of legal issues from indigenous property law to environmental protection agreements. His proficiency in multiple legal research platforms further solidifies the strength of our legal team.

Mark Watkins, a seasoned paralegal, has an impressive career with over 25 years of experience in the asbestos field and 10 years in the legal field, primarily focusing on mesothelioma injury cases. A graduate of the University of Central Missouri, Mark’s vast experience and dedication will serve as invaluable assets to the firm and its clients.

Chelsea Williams, the new Accounting Assistant, is a graduate of Kutztown University with a BA in Communication Studies. She brings over 15 years of industry experience in business operations from various sectors, such as food, hospitality, and staffing. Her passion for communication and organization will be instrumental in assisting with settlements and bookkeeping-related tasks.

Jeff Nelson, the new Digital Marketing Specialist, graduated cum laude from Drexel University in 2022 with a Bachelor of Science degree in Animation and Visual Effects. Jeff brings his expertise to our firm to enhance our online presence and ensure our clients can find the services they need easily and quickly.

“The diverse skills and experiences of our new team members will undoubtedly contribute to our ongoing mission of representing and fighting for the rights of asbestos victims,” says Dave Halpern, Founding Attorney of The Halpern Law Firm. “We’re confident that these additions will enable us to provide an even higher level of service to our clients.”

The Halpern Law Firm, with its offices across Pennsylvania, is known for its commitment and dedication to holding employers and asbestos manufacturing companies accountable for their actions. Over the past 30 years, Dave has investigated, litigated, and settled numerous mesothelioma and asbestos lung cancer cases, recovering substantial compensation for clients.

For more information about The Halpern Law Firm’s services for victims of asbestos exposure and mesothelioma or to schedule a free case review, visit their website at http://www.halpernlawyer.com or call 800-505-6000, available 24/7.

Share article on social media or email:

Health

HiDO Health Unveils AI Technology for Home Care, Reducing Health Costs by 67% and Hospitalizations by 80%

Leave a comment


“By shifting the focus towards personalized and proactive care in the comfort of homes, we can enhance outcomes, prevent unnecessary hospitalizations, and create a more sustainable and patient-centered healthcare,” said Charles Gellman, co-founder and CEO of HiDO.


EL DORADO HILLS, Calif. (PRWEB)

HiDO Health announced today its groundbreaking AI medical technology to alter the future of healthcare. With an unprecedented 67% decrease in health costs and an impressive 80% reduction in hospital admissions, this innovative platform sets a new standard for efficient and cost-effective home-based healthcare.

NEHI estimates the overall burden of suboptimal medication use exceeds $500 billion per year in the U.S.

“Home care plays a pivotal role in reducing healthcare costs while simultaneously improving the lives of patients. By shifting the focus towards personalized and proactive care in the comfort of homes, we can enhance outcomes, prevent unnecessary hospitalizations, and create a more sustainable and patient-centered healthcare,” said Charles Gellman, co-founder and CEO of HiDO.

Recognizing the growing need for accessible and affordable healthcare solutions, HiDO Health has developed an artificial intelligence platform, remote monitoring, and data analytics, to transform the way patients receive medical care in the comfort of their homes. This cutting-edge solution not only improves patient outcomes but also provides substantial cost savings for individuals and health plans. “Use of HiDO grants individuals, families and caregivers peace of mind that their loved ones are taking prescription medicines accurately, safely and as directed by their provider, thereby reducing the potential for medication errors” said Kathy Donneson, former Health Plan Administrator for CalPERS.

“Our goal is to empower individuals with the tools they need to receive personalized care in the comfort of their homes, fostering independence, and ensuring their well-being. HiDO is honored to help care for those who need assistance at home,” said Brandon Woolsey, co-founder and CTO of HiDO.

HiDO Health medical home technology is now available for deployment across the country. The company is actively seeking partnerships to extend the reach of its innovative solution and make a positive impact on the lives of seniors nationwide.

About HiDO Health

HiDO health, Inc. is transforming home care for the aging population. Founded in 2018, HiDO is the first company to automate home care without caregivers. For more information, visit http://www.hidohealth.com.

Share article on social media or email:

Health

Top New Jersey Weight Loss Doctor Announces Increase in Patients Seeking Prescription Medication for Weight Loss

Leave a comment


Hormone and Weight Loss Doctors of NJ - Logo

Hormone and Weight Loss Doctors of NJ – Logo

Our practice is one of very few New Jersey board certified providers that offer a plethora of prescription-based solutions for medical weight loss


WAYNE, N.J. (PRWEB)

Founder and medical director of the Wayne, New Jersey based Hormone and Weight Loss Doctors of NJ, Dr. Peter Balazs, announced today that his specialty weight loss practice has experienced a sharp increase in men and women seeking prescription medication (AOD-9604, CJC-1295/Ipamorelin, Mounjaro™, Ozempic®, semaglutide, tesofensine, and tirzepatide) for medical weight loss treatment. The medical weight loss programs offered at the Hormone and Weight Loss Doctors of NJ are FDA-approved to treat a variety of conditions.

Research from the US Preventive Services Task Force suggests that patients who underwent prescription-based medical weight loss treatment and concurrently practiced healthy lifestyle choices experienced reasonable weight loss, stating “studies of medication-based weight loss and maintenance interventions also reported greater weight loss or less weight regain in intervention compared with placebo groups”.

The Wayne, NJ based board certified medical weight loss physician noted, “Our practice is one of very few New Jersey board certified providers that offer a plethora of bioidentical prescription-based solutions for medical weight loss, as the nationwide shortage of the medication has put a strain on its availability. The FDA-approved medical weight loss treatments offered at our practice possess a strong history of sufficiently tackling weight management for patients who suffer from type 2 diabetes, as well as obesity”.

The influx of individuals seeking prescription medical weight loss consultations can be linked to the impact of the coronavirus pandemic, as many individuals in the U.S. underwent an intense and extended inactive lifestyle due to international government-mandated isolation. According to the National Institute of Health, “Psychological distress, pre-pandemic weight status, having children at home, and the amount of time since the last body weight check were all statistically significant predictors of pandemic weight gain”.

About Us

The board certified NJ weight loss & HRT specialist doctors of Hormone and Weight Loss Doctors of NJ offers prescriptions for medical weight loss including FDA approved Mounjaro, Ozempic, Semaglutide, and Tirzepatide. Peptide therapy for weight loss is also offered including AOD-9604 (Advanced Obesity Drug), CJC-1295 / Ipamorelin, and Tesofensine. We are also specialists in bio-identical hormone replacement therapy (BHRT / HRT) and offer treatments for Low-T, menopause, perimenopause, and other hormone imbalance conditions.

Dr. Peter Balazs

Hormone and Weight Loss Doctors of NJ

1777 Hamburg Turnpike

Suite 302-H

Wayne, NJ 07470

(973) 314-2905

https://www.hormoneweightlossdoctorsnj.com

Share article on social media or email:

Health

Mercy Nurses Recognized With 2023 Sisters of Mercy Nursing Awards

Leave a comment


(L-R): Sr. Helen Amos; Dr. David Maine; Linda Macken; Maritza Sanchez-Ordonez; Kya Taylor, RN; Graze Bautista; Susan Finlayson; Aarika Pakulski (photo only); Stacey Brull.

(L-R): Sr. Helen Amos; Dr. David Maine; Linda Macken; Maritza Sanchez-Ordonez; Kya Taylor, RN; Graze Bautista; Susan Finlayson; Aarika Pakulski (photo only); Stacey Brull.

“Congratulations to all…Your continued support and commitment to Mercy is why we continue to be one of the top 8% of hospitals in the nation for excellent nursing care.” — Stacey Brull, DNP, RN, NE-BC, Mercy Vice President and Chief Nursing Officer


BALTIMORE (PRWEB)

As part of the annual recognition of National Nurses Week (May 1-7, 2023), Mercy Medical Center in Baltimore, MD, recently hosted The Sisters of Mercy Nursing Awards on Thursday, May 18th. This year’s recipients were:

Aarika Pakulski, BSN, RN, Emergency Department: Nursing Visionary Award, presented in the spirit of Sister Mary Damian Faller, RSM

Kya Taylor, RN, Bunting 14th floor-Specialty Surgery: Compassionate Caregiver Award, presented in the spirit of Sister Mary Thecla Lancaster, RSM

Maritza Sanchez-Ordonez, RN, C-EFM, Labor & Delivery: Nursing Hospitality Award, presented in the spirit of Sister Elizabeth Anne Corcoran, RSM

Linda Macken, RN, OCN, Outpatient Chemotherapy: Community Impact Award, presented in honor of Sister Helen Amos, RSM

and Graze Bautista, MSN, RN, CPAN, CAPA, Charles Crane Surgery Suite, Post Anesthesia Care Unit (PACU): Nursing Leadership Award, presented in honor of Sister Mary Thomas Zinkand, RSM

Stacey Brull, DNP, RN, NE-BC, Vice President and Chief Nursing Officer, made both the welcoming and closing remarks at the event with further remarks by Susan Finlayson, DNP, RN, NE-BC, Senior Vice President.

“Congratulations to all of the nominees and recipients of the 2023 Nursing Excellence Awards. Your continued support and commitment to Mercy is why we continue to be one of the top 8% of hospitals in the nation for excellent nursing care,” Brull said.

Dr. David N. Maine, Mercy Health Services President and CEO, recognized the entire Mercy nursing team for “delivering top-notch, empathetic care to our patients and their families.”

Despite the challenges raised by the COVID-19 pandemic during the past three years, Mercy nurses have excelled, achieving a third consecutive recertification of Magnet Recognition® by the American Nurses Credentialing Center (ANCC). In addition, Mercy has also earned many recent awards and distinctions including:

Healthgrades: Mercy ranked among the top 50 hospitals in the United States for surgical care, and #1 in Maryland.

American Nurse: Mercy received the 2022 All-Pro Nursing Team Award’s top honor.

The Maryland Bariatric Center at Mercy earned national accreditation from the American College of Surgeons.

Newsweek: Mercy was named the Most Trustworthy Company in America 2023, #1 in Maryland and #3 nationally.

Mercy also earned a spot among America’s Greatest Workplaces for Women in 2023.

“These accolades and recognitions attest to the unwavering commitment and dedication of Mercy’s nurses and staff. They remain devoted to providing superior, compassionate care to our patients, and these awards serve as an acknowledgment of their success,” Dr. Maine added.

Founded in 1874 by the Sisters of Mercy, Mercy Medical Center is located in downtown Baltimore City, about six blocks from Baltimore’s famed Inner Harbor. A university-affiliated teaching facility, Mercy is a Catholic hospital with a national reputation for women’s health care, orthopedics, and other specialties. Mercy is home to the renowned Weinberg Center for Women’s Health & Medicine, and the $400+ million Mary Catherine Bunting Center. For more information, visit http://www.mdmercy.com, and MDMercyMedia on Facebook and Twitter, or call 1-800-M.D.-Mercy.

Share article on social media or email:

Health

Mays Cancer Center conducts only clinical trial in America of a specific drug combination for lethal brain cancer glioblastoma

Leave a comment


“GBM comes back after treatment in almost all patients, and when it does, survival is extremely poor. There is a desperate need for more therapies to treat these patients.” — William Kelly, MD, Mays Cancer Center, UT Health Science Center San Antonio


SAN ANTONIO, Texas (PRWEB)

The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM). The Mays Cancer Center, one of the four National Cancer Institute-Designated Cancer Centers in Texas, is the only center in America to conduct this trial.

Andrew Brenner, MD, PhD, professor of medicine at the UT Health Science Center San Antonio and a specialist in both breast cancer and malignancies of the brain and spinal cord, initiated the clinical trial.

“Glioblastoma is the most common and unfortunately the most aggressive primary brain tumor,” Brenner said. “The average survival for a newly diagnosed GBM is 20 months, and that’s only a four-month improvement in survival from 2005, when we began following surgery with chemotherapy and radiation.”

Deadly disease

Glioblastoma has claimed the lives of many well-known figures. U.S. Sen. Edward M. Kennedy died of GBM in 2009. Beau Biden, son of President Joe Biden, succumbed to the disease in 2015. Sen. John McCain lost his battle with GBM in 2018.

“That is the landscape in which we work,” said William Kelly, MD, Mays Cancer Center medical oncologist and assistant professor of medicine at UT Health Science Center San Antonio. “GBM comes back after treatment in almost all patients, and when it does, survival is extremely poor. There is a desperate need for more therapies to treat these patients.”

The treatment consisted of a standard-of-care chemotherapy called bevacizumab (brand name Avastin) combined with a small-molecule fatty acid synthase inhibitor called TVB-2640 (or Denifanstat). Glioblastoma tumors rely on their ability to make fatty acids for growth.

The Mays Cancer Center enrolled and treated 25 patients with GBM. Side effects such as rashes, dry eye and fatigue were mild, and researchers noted an improvement in six-month progression-free survival.

Hope tempered with realism

No current therapy improves survival in recurrent GBM. Indeed, the overall survival of participants in the Mays Cancer Center study was not statistically significant compared to historic controls (patients with high-grade GBMs who weren’t in the study and were treated with bevacizumab only).

However, the fact that the drug combination was able to arrest cancer progression for six months in a greater number of patients with high-grade GBM was noteworthy. “This gives us hope, although we are always simultaneously realistic about the disappointing history of treating these diseases,” Kelly said.

Results were published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Acknowledgments

Funding for this research was provided by a National Cancer Institute P30 grant [CA054174] as well as an endowment from the Kolitz Foundation. The Proteomics and Metabolomics Facility was supported in part by a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) [RP130397] and two National Institutes of Health grants [1S10OD012304-01 and P30CA016672]. Biostatistical analysis was supported in part by a CPRIT core facility grant [RP160732]. TVB-2640 was provided by Sagimet Biosciences. The authors thank the patients for their trust and participation.

Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

William Kelly, Adolfo Enrique Diaz Duque, Joel Michalek, Brandon Konkel, Laura Caflisch, Yidong Chen, Sarath Chand Pathuri, Vinu Madhusudanannair-Kunnuparampil, John Floyd II, Andrew Brenner.

First published: May 9, 2023, Clinical Cancer Research

https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-2807/726341

In addition to their affiliation with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio, multiple authors are appointed in these academic departments and research institutes of the university’s Joe R. and Teresa Lozano Long School of Medicine: Department of Medicine, Department of Population Health Sciences, Department of Neurosurgery, Department of Cell Systems and Anatomy, and Greehey Children’s Cancer Research Institute.

The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is one of the country’s leading health science universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have graduated more than 41,100 alumni who are leading change, advancing their fields and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways “We make lives better®,” visit UTHealthSA.org.

The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is one of only four National Cancer Institute-designated Cancer Centers in Texas. The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas. To learn more, visit http://www.UTHealthSAMDAnderson.org.

Stay connected with the Mays Cancer Center on Facebook, Twitter, LinkedIn, Instagram and YouTube.

Share article on social media or email:



Health

Hammes recognized as one of the Best Places to Work in Healthcare in 2023

Leave a comment


News Image

We consider it a tremendous honor and accomplishment to be recognized at a national level as one of the best places to work in healthcare.


MILWAUKEE (PRWEB)

Hammes has been selected by Modern Healthcare as one of the 2023 Best Places to Work in Healthcare. This was Hammes’ first year participating in the annual award program, which identifies and recognizes outstanding employers in the healthcare industry nationwide. Modern Healthcare partners with Workforce Research Group on the assessment process, which includes an extensive employee survey.

“An uncertain economy, staffing shortages and increasing demands for flexibility and remote work opportunities are forcing every business in the industry to focus on attracting and retaining talent in unprecedented ways,” said Dan Peres, president of Modern Healthcare. “The 2023 Best Places to Work winners proved the value of understanding what employees want—and need—today. The healthcare industry is going through a period of extraordinary change. Having the right people in place is more critical than ever, and the winning workplaces understand that taking care of employees is central to business success.”

“We consider it a tremendous honor and accomplishment to be recognized at a national level as one of the best places to work in healthcare,” said Patrick Hammes, Managing Principal. “As our organization has grown significantly in support of our healthcare clients, we view this recognition as a testament to the culture of excellence we diligently strive to maintain, in large part by attracting and retaining top-notch talent.”

The complete list of the 2023 Best Places to Work in Healthcare winners is available at ModernHealthcare.com/bestplaceslist.

About Hammes

Founded in 1991, Hammes is a vertically integrated real estate solutions platform specializing in healthcare real estate strategy and planning, project management, development, investment, and property management. As a testament to our deep healthcare industry experience, Hammes has been recognized as one of the nation’s leading healthcare developers by Modern Healthcare’s Construction & Design Survey for 25 consecutive years—including 20 years as No. 1—and by Revista’s Outpatient Healthcare Real Estate Development Report. Headquartered in Milwaukee, Wisconsin, Hammes provides services through a network of regional offices strategically located across the United States. http://www.hammes.com

Share article on social media or email:

Health

PlatformQ Health Presenting at ASCO Poster Discussion Session on Diversity and Clinical Trial Enrollment

Leave a comment


“We have a long-standing focus on improving equitable representation in clinical trials,” said Robert Rosenbloom, PlatformQ Health President and CEO. “We’re incredibly honored for our work to be selected for inclusion in this discussion at ASCO, the world’s largest cancer research conference.”


BOSTON and CHICAGO (PRWEB)

PlatformQ Health will be presenting DEI-focused research at the 2023 ASCO Annual Meeting session titled, “Representing the Underrepresented: Improving Clinical Trial Enrollment”. PlatformQ Health Senior Medical Director, Tariqa Ackbarali, PhD, MS, will join faculty from leading medical institutions to share insights on this pressing national healthcare issue.

Lack of equitable representation of patients across different ethnic, racial, and age groups impedes the ability to ensure the safety and efficacy of new therapies for all patients. In addition, the passage of the Food and Drug Omnibus Reform Act (FDORA) in late 2022 now requires biopharma companies to submit a diversity action plan to FDA in advance of launching a new pivotal study, raising the stakes for deeper engagement on practical solutions.

“We have a deep commitment to health equity, and a long-standing focus on improving equitable representation in clinical trials,” said Robert Rosenbloom, PlatformQ Health President and CEO. “We’re incredibly honored for our work to be selected for inclusion in this important discussion at ASCO, the world’s largest cancer research conference.”

Since 2018, PlatformQ Health has created digital education focused on clinical trial awareness and improvement of diverse representation in trials, empowering both clinician and patient communities with insights for action. In the ASCO panel discussion – being held from 4:30-6:00 PM on June 3 – Dr. Ackbarali will share outcomes from the company’s recent educational initiative focused on diversity in breast and lung cancer trials.

The discussion session will take place in auditorium E350, located on level 3 of the McCormick Place Lakeside Center, East Building in Chicago.

About PlatformQ Health

PlatformQ Health is the leading provider of interactive digital medical education for clinicians, patients, and caregivers. To improve patient care, PlatformQ Health creates video-based educational modules with premier clinician and patient advocacy partners, so learners can better understand conditions, available treatment options, and the latest research. The company’s proprietary platform allows learners to engage in real-time discussion with scientific, research, and patient care experts – and the integrated learning solution enables advocates, administrators, health systems and plans, foundations, societies, member organizations, and associations to measure the impact of their education.

For more information, visit http://www.platformqhealth.com.

Share article on social media or email:

Health

Thought Technology Ltd. to Host Biofeedback and Neurofeedback Workshops at its Montreal Headquarters

Leave a comment


News Image

Clinicians trained in biofeedback typically use clinical grade equipment to perform a psychophysiological assessment and can bring forth a much deeper level of knowledge about what metrics are important.


MONTREAL (PRWEB)

Thought Technology, an international leader in the field of psychophysiological monitoring equipment, is offering two upcoming workshops at their Montreal headquarters, designed to provide clinicians with the fundamentals of Biofeedback and neurofeedback in order to add or enhance their knowledge of these techniques for their practice.

More and more, people are looking to technology to stay on top of their personal health metrics, sometimes without a deep understanding of what the data means. Clinicians trained in biofeedback typically use clinical grade equipment to perform a psychophysiological assessment and can bring forth a much deeper level of knowledge about what metrics are important, how to use the information learned from assessing specific metrics, and how to help their clients lead healthier lives or perform at a higher level.

This course focuses on the typical parameters used in biofeedback, such as heart rate, temperature, skin conductance, blood volume and muscle activity, along with how to use this information in practice. The neurofeedback course will focus on EEG and the areas of the brain that are associated with different disorders such as ADHD, anxiety and depression, among others, and how neurofeedback can be used to ameliorate these conditions and optimize brain activity.

Both courses will be instructed by Dr. Manuel Halter and registration is now open.

Biofeedback Certificate Course

Date: July 14-15, 2023

Time 8:30-5:30 EDT

Location: Montreal, QC

Neurofeedback Certificate Course

Date: July 16-17, 2023

Time: 8:30-5:30 EDT

Location: Montreal, QC

About the Instructor

The workshops will be instructed by Dr. Manuel Halter, an experienced neuroscience researcher who has worked with the U.S. military as well as universities to develop cutting edge assessment and training programs in cognitive neuroscience and human performance. A Green Beret and a retired member of the U.S. Army’s Special Forces, Dr. Halter, continued his education and completed his degree of Doctor of Philosophy with a specialization in talent performance optimization. He also holds an undergraduate degree in Psychology, a Master of Arts in Developmental Psychology, and a Master of Arts in Clinical Neuropsychology. Dr. Halter currently works at InMindOut supervising the neurofeedback and QEEG programs in addition to teaching practitioner’s biofeedback, neurofeedback, and QEEG.

About Successful Practitioner

Successful Practitioner’s philosophy is to break through the mental health epidemic using today’s advanced health technology. Our mission is to empower health and wellness providers to transition away from traditional medicine to a more advanced whole body preventative healthcare. We believe in the importance of embracing the use of technology to help prevent issues before they begin, identify existing issues, and repair any damage that has occurred to help the community live a fuller, healthier, and happier life. Successful Practitioner enhances professionals’ abilities to provide better assessment and care options to their clients. Successful Practitioner’s goal is to share its passion and decades of resources with professionals so they can best serve their immediate communities.

Successful Practitioner helps passionate professionals navigate the challenges of becoming properly educated, equipped, and prepared to provide gold standard wellness services including education in Biofeedback, Neurofeedback, and QEEG as well as mentorship and business consulting. Successful Practitioner’s education is powered by InMindOut.

About InMindOut Emotional Wellness Center

InMindOut Emotional Wellness Center partners with Successful Practitioner to offer educational and professional services to biofeedback, neurofeedback, QEEG practitioners, as well as other mental health and wellness professionals. We take a team approach, collaborating with the best instructors and educational providers in the fields of neuroscience, psychology, ethics, and behavioral science to provide the latest empirically supported research and hands-on experiences.

The InMindOut Emotional Wellness Center is an unbiased educational provider. All courses we offer are approved certificate courses by the following boards; Biofeedback Certification International Alliance (BCIA) and International QEEG Certificate board (IQCB). Courses are offered in various formats including online and hybrid hands-on options.

About Thought Technology Ltd.

Founded in 1975, Thought Technology is the world’s leading biofeedback and physiological instrument manufacturer. Its products are used as an essential part of many therapeutic treatments and clinical assessment protocols in over 85 countries and are used by tens of thousands of clinicians in thousands of medical institutions.

Always supportive of new research and development ideas, Thought Technology Ltd. has encouraged a number of special interest groups and clinicians to create cutting edge applications for its instrumentation. Thought Technology Ltd. equipment is now being used in telemedicine, web-based monitoring and biofeedback, sports training, research in human-machine interface, physiology-driven multimedia environments and virtual reality. Constantly striving to improve the quality of the products and services, TTL has obtained, and maintains, ISO 13485, and CE certification for the organization and products.

Share article on social media or email:

Health

Mytonomy Takes Home 10 Wins at the 44th Annual Telly Awards

Leave a comment


Mytonomy’s achievements at the Telly Awards underscore our dedication to transforming patient education and engagement through innovative video content. – Dr. Seema Kumar, M.D., M.P.P., Mytonomy Medical Director and Head of Clinical Effectiveness


BETHESDA, Md. (PRWEB)

Mytonomy, Inc., a leading enterprise SaaS solution for video-based patient education and engagement, announced today that its evidence-based, microlearning patient education and engagement platform has received 10 prestigious honors at the 44th Annual Telly Awards. The Telly Awards recognize excellence in video and television across all screens and are judged by industry leaders from renowned video platforms, television networks, streaming services, and production companies.

Mytonomy’s content production adheres to the highest standards of evidence-based medicine and is developed by an award-winning clinical and studio production team. The platform was built to meet the needs of today’s health practitioners and patients by providing content in concise and compelling doses. The effectiveness of Mytonomy’s unique approach has been validated by over 10 real world data or IRB studies, supporting the company’s evidence-based microlearning method in improving patient communication, education, and engagement.

“Mytonomy is dedicated to empowering patients and supporting practitioners by delivering high quality, clinically validated video education that uniquely meets the needs of today’s digital age. Our goal is to improve healthcare outcomes and patient journeys by providing accessible, evidence-based information,” said Dr. Seema Kumar, M.D., M.P.P., Mytonomy Medical Director and Head of Clinical Effectiveness. “We are honored to be recognized with these Telly Awards, which reaffirm our commitment to delivering high-quality, impactful content. This achievement further motivates us to continue pushing boundaries and leveraging innovative technologies to transform the way patients and healthcare professionals connect and collaborate.”

This year’s Telly Awards submissions topped previous years, with global entries bordering 13,000 from top video and television content producers such as Airbnb, Audible, BET Networks/BET Digital, BritBox, Disney, FEMA, Gaumont, Golden State Warriors, MediaMonks, NASA, National Geographic Society, Netflix, Paramount, PBS Digital Studios and more. The Telly Awards winners represent creators and talents who stand out during a time when screens often bring more confusion than quality into our lives. These creators and innovators are building a future through their creativity, celebrating the ways video is being used as a force for good and how emerging technologies are pushing the boundaries of innovation.

“The caliber of the work this season coming from creators such as Mytonomy truly has reflected the theme of breaking out and standing out,” said Tellys Executive Director Sabrina Dridje. “Our industry is experimenting with new technologies like never before, crafting truly compelling stories to draw attention to some of the world’s most pressing issues, and companies big and small are turning to more sustainable practices to break the cycle of past production processes.”

The following Mytonomy videos have been recognized with the 2023 Telly Awards:

  • Breast Cancer Patient Testimonial – GOLD

  • How Do I Know If I Can Be a Kidney Donor? – SILVER

  • I’m a Kid With an Insulin Pump – SILVER

  • Immunosuppressants and Your Immune System- SILVER

  • Proper Hand Cleansing – SILVER

  • What Is Diastolic Heart Failure? – SILVER

  • Blood Drive – BRONZE

  • Connecting With My Infant in the CICU – BRONZE

  • Preventing Future Hospital Admissions Due to Sepsis – BRONZE

  • Providing Mouth Care – BRONZE

“Mytonomy’s achievements at the Telly Awards underscore our dedication to transforming patient education and engagement through innovative video content. By consistently striving for excellence, we continually establish new benchmarks and make valuable contributions to the progress of healthcare,” added Kumar.

About Mytonomy

Mytonomy, Inc., based in Bethesda, MD, is a leader in enterprise cloud solutions for video-based patient engagement and education. Mytonomy creates efficiencies for doctors and nurses by streaming broadcast-quality, evidence-based video education to patients and their families so that they can lead healthier, happier lives. Mytonomy can rapidly scale across the inpatient and outpatient setting and help patients transition from hospital to home.

Mytonomy’s Cloud for Healthcare is fully interoperable with all major EMRs and CRM solutions, covering over 100 conditions with more than 3,000 episodes, all delivered via a single engagement platform spanning the patient journey. Mytonomy can rapidly scale across the inpatient and outpatient setting and help patients transition from hospital to home. To learn more about Mytonomy, please visit http://www.mytonomy.com.

About The Telly Awards

The Telly Awards is the premier award honoring video and television across all screens. Established in 1979, The Telly Awards receives over 12,000 entries from all 50 states and 5 continents. Entrants are judged by The Telly Awards Judging Council—an industry body of over 200 leading experts including advertising agencies, production companies, and major television networks, reflective of the multiscreen industry The Telly Awards celebrates. Partners of The Telly Awards include Green The Bid, SeriesFest, Video Consortium, Ghetto Film School, We Are Parable, Future of Film, NAB, Stash, NYWIFT, Production Hub with support from The Commercial Director’s Diversity Program.

Share article on social media or email:

Society: Christianity

Dino Rizzo, ARC Churches Co-Founder, Announces Recent Interview with Brainz Magazine

Leave a comment



BIRMINGHAM, Ala. (PRWEB)

Dino Rizzo, the co-founder and executive director of ARC (Association of Related Churches), is excited to announce that he was featured in a recent story for Brainz Magazine.

Dino Rizzo, who has more than 35 years of ministry experience and co-founded Healing Place Church with his wife DeLynn, shared with Brainz Magazine insights on ARC churches and his vision for church planting.

As part of the interview, Rizzo pointed out that 20 years ago, when ARC (Association of Related Churches) began, he wasn’t aware of other church planting organizations, making this an important place to start. Since that time, the organization has helped launch more than 1,000 churches.

The goal of the organization, Rizzo said, is to create relationships with ARC church-planting couples and their teams so they can thrive and spread the word of Jesus to members of the community.

He also said that ARC church planting success depends on the hard work, culture, leadership, and connection with people that leaders are able to establish. Dino Rizzo also said, though, that there’s a “God factor” that’s part of success. He told Brainz Magazine that God sends unique waves and that “we need to pay attention to our own wave instead of comparing it to others.”

In addition to discussing his vision for ARC churches, Rizzo discussed his passion for serving. That passion, he said, comes from the fact that he was reached through outreach, to begin with. If he didn’t experience that, he never would’ve started a church on his own.

As Dino Rizzo explained:

“Outreach is about noticing a need, pain or suffering and coming alongside to side. We want to empower church leaders to realize there are people around them waiting for someone to be the hands and feet of Jesus. It doesn’t take a lot of money or resources to make a difference.”

Other topics that Rizzo discussed in his Brainz Magazine interview were some of the major challenges he’s seeing this ARC church planting season and the one piece of advice he’d give young church leaders.

Brainz Magazine is a global digital magazine focused on exclusive information, articles, and interviews on lifestyle, leadership, personal development, and entrepreneurship. Its mission is to advocate for people’s success and happiness by providing content that motivates, provides answers they seek, and inspires.

Dino Rizzo is the author of the book “Serve Your City” and founded the organization Servolution. In addition to his roles and ARC (Association of Related Churches) and Healing Place Church, he also serves on the senior leadership team at Church of the Highlands.

To read Dino Rizzo’s full interview with Brainz Magazine, please visit the magazine’s website.

About Dino Rizzo

Dino Rizzo, a 35-year ministry veteran, co-founded Healing Place Church with his wife, DeLynn, where he served as senior pastor for two decades. Through his passion for inspiring believers to serve their communities, Dino Rizzo founded Servolution and authored “Serve Your City.” Rizzo serves as the Executive Director of ARC (Association of Related Churches), which has planted more than 1000 churches worldwide, and is on the Senior Leadership Team at Church of the Highlands.

About ARC (Association of Related Churches)

ARC (Association of Related Churches) is a cooperative of independent churches from different denominations, networks, and backgrounds who strategically resource church planters and pastors to help them reach people with the message of Jesus. ARC exists to see a thriving church in every community, reaching people with the message of Jesus. Since its beginning in 2000, ARC has grown into a global organization and has helped plant more than 1,000 churches.

Share article on social media or email: